行情

TGTX

TGTX

TG Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

13.70
-0.33
-2.35%
盘后: 13.71 +0.01 +0.07% 17:18 01/17 EST
开盘
14.53
昨收
14.03
最高
14.89
最低
13.61
成交量
298.83万
成交额
--
52周最高
14.89
52周最低
3.870
市值
13.24亿
市盈率(TTM)
-6.2157
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TGTX 新闻

  • 波音接到美国空军警告:不满的还有我们
  • 新浪美股.4小时前
  • 收盘:财报季开局良好美股收高 道指本周累涨1.82%
  • 新浪美股.4小时前
  • 马斯克与谁共舞?
  • 中国经营报.4小时前
  • 美欧贸易谈判前景积极 欧洲股市创下历史新高
  • 新浪美股.5小时前

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

TGTX 简况

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
展开

Webull提供TG Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。